narmac - Here are masila"s notes from the Resverlogix Special Meeting June 30 at 9am also on page 9 of the Link Libray

A bit of change in plans around the trial. Will now include both atorvastatin and rosuvastatin users so that they can get further understandings on why it works well with one and not the other. Anywhere from 2400-4800 patients, dosing up to 2 yrs with average of 18 months. 250 of those likely in China territories with funding provided by Shenzen.

They also said dosing up to 2 years, not completion by end of 2017.

tada